Phase III Randomized, Double-Blinded Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)
The purpose of this phase III trial is to evaluate the efficacy of cabozantinib compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery.
Study ID: NCI-2017-02297
Trial Phase: Phase III
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Cabozantinib